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The World Health Organisation (WHO) classification (2000) is widely used to classify neuroendocrine carcinomas (NECs), yet its
prognostic value needs to be confirmed. In this study, patients with metastatic NECs (n¼119) were classified according to WHO
guidelines into well differentiated and poorly differentiated (WDNECs and PDNECs). Histological differentiation based on WHO
criteria had the highest impact on overall survival (OS) (PDNECs:WDNECs hazard ratio (HR)¼4.02, P¼0.02); however, PDNECs
represented only a small percentage of patients (8%). In a WDNEC-restricted analysis, abnormal liver function tests (LFTs) and
elevated urinary 5-hydroxyindoleacetic acid (u5HIAA) were independent prognostic factors for survival (HR¼2.65, P¼0.006 and
HR¼2.51, P¼0.003, respectively) and were used to create a WDNEC-specific prognostic model (low risk¼both normal,
intermediate risk¼one of them abnormal, high risk¼both abnormal). Low-risk WDNECs had the most favourable prognosis
(median OS, mOS 8.1 years), which was significantly better compared to both intermediate-risk and high-risk WDNECs (mOS 3.2
and 1.4 years, with P¼0.01 and Po0.001, respectively). High-risk WDNECs displayed the shortest OS (1.3 years), which was similar
to that of PDNECs (P¼0.572). This analysis supports the prognostic value of WHO classification for metastatic NECs arising from
the gastroenteropancreatic tract; however, risk stratification using readily available u5HIAA and LFTs may be necessary for the
heterogeneous group of WDNECs.
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Neuroendocrine tumours (NETs) are a group of tumours
originating from cells of the diffuse endocrine system (DES). The
DES includes a number of endocrine cells spread throughout all
the body with the ability to secrete several bioactive amines and
peptides. Intracellular structure is characterised by cytoplasmic
electron-dense granules and immunohistochemistry shows the
expression of antigens commonly found in nerve elements (e.g.
chromogranin A (CgA), NSE, synaptophysin, PGP 9.5) (Rindi et al,
2000; Rindi and Kloppel, 2004). Diffuse endocrine system of
gastroenteropancreatic (GEP) tract represents the largest portion
with at least 15 different types of neuroendocrine cells identified.
Most common NET, the carcinoid tumour, originates from
enterochromaffin cells and characteristically secretes serotonin,
tachykinins and other mediators responsible for the ‘carcinoid
syndrome’ (for a review see Kulke and Mayer, 1999). Other
hypersecretory syndromes (HSS) may be associated with NETs
(e.g. insulinomas and gastrinomas) but in approximately 50% of
cases they are ‘non-functioning’ (Plockinger et al, 2004).
In 2000, in consultation with the WHO, a revised classification
for NETs was developed to unify histological diagnostic criteria
and overcome the ambiguity of terms such as APUDoma,
carcinoid and islet cell tumour (Solcia et al, 2000). The new
WHO classification encourages the application of a unique scheme
for all anatomical sites (lungs, thymus, gut and pancreas) and the
fully comprehensive term of ‘neuroendocrine tumour’ (or ‘endo-
crine tumour’) over the above mentioned names (Rindi and Bordi,
2003; Rindi and Kloppel, 2004). Three main categories are
identified: (1) well-differentiated neuroendocrine tumour (loca-
lised to the organ or bowel wall), (2) well-differentiated
neuroendocrine carcinoma (WDNEC, locally advanced or meta-
static) and (3) poorly differentiated neuroendocrine carcinoma
(PDNEC, displaying high-grade histology regardless of tumour
stage).
The classification provides a useful framework to study and
classify NET patients, but its clinical relevance is not yet fully
defined. The aim of this study was to assess the prognostic value of
the WHO classification for metastatic NEC of the GEP tract and
to evaluate whether other clinical, histological or biochemical
parameters give additional prognostic information for this group
of patients.
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Patients
Records of patients with a histological diagnosis of NET referred
to the Royal Marsden Hospital (RMH) between April 1974 and
May 2005 were retrospectively reviewed. Patients with metastatic
disease arising from GEP tract were eligible for the study.
Unknown primary site (UPS) tumours with intraabdominal
metastases as the main site of disease were also included. Patients
with a concomitant diagnosis of adenocarcinoma were excluded.
All histological materials were reviewed by a single histopatho-
logist (AW) and classified, according to the WHO classification,
into well and poorly differentiated tumours. A distinction between
carcinoid and non-carcinoid NETs was also made.
Baseline data including sex, age, tumour primary site, sites of
metastases, performance status (PS), presence of HSS, routine
haematology and biochemistry, 24h level of urinary 5-hydro-
xyindoleacetic acid (u5HIAA) and other circulating tumour
markers, uptake of radiotracer (radiolabelled metaiodobenzyl-
guanidine and/or octreotide) and first treatment modality were
recorded. Data were considered evaluable if collected within 3
months from the diagnosis and before any active treatment.
Patients were grouped by primary site according to the
traditional classification of foregut, midgut and hindgut; a fourth
group was formed by UPS tumours. Metastatic sites of disease
were all grouped into nine categories (liver, pelvis, retroperito-
neum, mesentery, peritoneum, mediastinum, lungs, bone, other).
For patients diagnosed from 1994 onwards, staging included CT
scan of the thorax abdomen and pelvis. However, for patients
referred before 1994, chest radiograph and liver ultrasound were
also considered acceptable for the purpose of this analysis. Four
main HSS were recognised for functioning tumours: Carcinoid,
Zollinger-Ellison, Cushing and Insulinoma-related syndrome.
Performance status was measured using the Eastern Cooperative
Oncology Group (ECOG) scale.
Biochemical parameters of liver function tests (LFTs) and
u5HIAA were analysed. Liver function tests included bilirubin,
alanine aminotransferase (ALT) and gamma-glutamyl-transferase
(gammaGT) and an increase of grade 2 or more according to
CTCAEv3.0 (Common Terminology Criteria for Adverse Events
v3.0, http://ctep.cancer.gov/reporting/ctc.html) in at least one of
the three LFT variables was required to define the tests as
significantly abnormal. This was 2.5 times the upper limit of
normal (ULN) for ALT and gammaGT and 1.5 times the ULN for
bilirubin. Urinary 5-hydroxyindoleacetic acid was considered as
the primary tumour marker for both carcinoid and non-carcinoid
tumours; however, data from other markers (i.e. CgA, CEA,
mucins, specific hormones) were also recorded when available.
24h u5HIAA levels were defined as significantly elevated when
higher than two times ULN. This cutoff was chosen because it
corresponded to the median value. Data pertaining to first
treatment modality were classified in five main categories: surgery,
chemotherapy, biological therapy, radiotherapy and symptomatic
therapy.
Statistics
The primary statistical end point was overall survival (OS), defined
as the interval time between diagnosis and death from any cause or
last follow-up. The hazard ratios (HRs) between subgroups of
patients with different features were estimated by Cox regression
analysis, which was used for both univariate and multivariate
analysis. Survival analysis was performed using the Kaplan–Meier
method including confidence limits. The level of significance was
0.05 for all statistical tests. All analyses were performed using
commercially available software (SPSS version 12, SPSS Inc.,
Chicago, IL, USA). Approval for the study was obtained from the
local research ethics committee and committee for clinical research
(study number 05/Q0801/167).
RESULTS
Patient characteristics
A total of 423 consecutive neuroendocrine patients were identified
of whom 119 patients presenting with metastatic disease arising
from the GEP tract at diagnosis were eligible for this analysis.
Among them, 25 patients with an unknown primary site tumour
(UPS tumours) were included as they had predominantly
abdominal disease (usually liver and peritoneal surface) (Table 1).
The median age was 59 years (range 28–86 years); the male to
female ratio was unity (1:1). The most common primary site was
ileum (in 33% of patients), followed by pancreas (22%). According
to the embryological classification of carcinoid tumours, midgut
tumours were most common (43%). A high percentage of UPS
NECs were observed (31%). The liver was involved as a site of
metastasis in 72% of cases (37% liver-only, 35% with other organ
metastases). After histopathological review, nine patients (8%)
were classified as PDNEC and 110 (92%) as WDNEC.
At diagnosis, 38% of patients presented with symptoms and
signs suggestive of HSS, in all of these the relevant hormone was
elevated in the bloodstream. Performance status was available only
for 55 patients (46%); it was therefore not included as variable
in Cox-regression analysis. However, a PS of 3–4 was observed in
only two patients.
Liver function tests and u5HIAA levels were not available for 12
and 19% of patients, respectively. Interestingly, for 10 patients with
Table 1 Characteristics of 119 metastatic neuroendocrine tumour
patients included in the analysis. Absolute number of patients (percentage
within each group)
Gender Hypersecretory syndrome
Male 59 Functioning 45 (38%)
Female 60 Non-functioning 74 (62%)
Age at diagnosis Laboratory
Median 59 years ALT
Range 28–86 42.5 ULN 4
Primary site o 2.5 ULN 102
Foregut NA 13
Pancreas 25 (22%) GammaGT
Stomach 1 (1%) 42.5 ULN 19
Midgut o 2.5 ULN 86
Ileum 40 (33%) NA 14
Right colon 5 (4%) Bilirubin
Appendix 5 (4%) 41.5 ULN 6
Ceacum 3 (2%) o 1.5 ULN 100
Hindgut NA 13
Left colon 3 (2%) LFTs
Rectum 1 (1%) Raised 21
UPS GI 36 (31%) Normal 84
Site of metastasis NA 14
Liver 44 (37%) u5HIAA
Liver+other sites 42 (35%) 42 ULN 48
Other sites 33 (28%) o 2 ULN 48
Differentiation NA 23
Well-differentiated 110 (92%) First clinical management
Poorly differentiated 9 (8%) Symptomatic treatment 18 (15%)
Carcinoid vs non-carcinoid Biological therapies 15 (13%)
Carcinoid 78 (66%) Chemotherapy 31 (26%)
Non-carcinoid 41 (34%) Surgery 53 (45%)
Radiotherapy 2 (1%)
ALT¼alanine aminotransferase; gammaGT¼gamma-glutamyl transferase; LFTs¼
liver function tests; NA¼not assessable; u5HIAA¼urinary 5-hydroxyindole acetic
acid; ULN¼upper limit of normal; UPS GI¼unknown primary site with abdominal
lesions as main site of disease. LFTs raised: at least one of ALT, bilirubin or gammaGT
abnormal.
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showing a non-carcinoid tumour. The first therapeutic decision
was debulking surgery for 45% of patients, chemotherapy for 26%,
biological therapy (interferon and/or somatostatin analogues) for
13% and radiotherapy for 1%. Fifteen percent of patients were
initially managed expectantly.
Univariate analysis
Sex, age, primary site, sites of metastasis, histological differentia-
tion, presence of HSS, LFTs and u5HIAA levels were considered as
potential prognostic variables in the univariate analysis for OS
(Table 2). Histological differentiation displayed the highest impact
on prognosis, with an HR (PDNEC/WDNEC) of 3.37 (95% CI
1.50–7.55, P¼0.003). Relative risk of death was also significantly
higher for patients with abnormal u5HIAA or LFTs (HR 1.87, 95%
CI 1.08–3.24, Po 0.025 and HR 2.08, 95% CI 1.17–3.72, Po 0.013,
respectively), whereas midgut NETs were associated with a
favourable prognosis when compared to the entire group of
‘non-midgut’ tumours (HR 1.74, 95% CI 1.08–2.81, Po 0.023).
Relative risk of death was not significantly affected by sex, age,
carcinoid nature of the tumours and presence of HSS.
Multivariate analysis
Prognostic factors found to be statistically significant at univariate
analysis were selected for multivariate analysis (Table 2). Histo-
logical differentiation was confirmed to be the most powerful
independent prognostic factor, with a risk of death nearly four
times higher when PDNEC was diagnosed (HR 4.02, 95% CI 1.26–
12.82, P¼0.02). Elevated u5HIAA levels and abnormal LFTs were
also demonstrated to be independently associated with a poor
outcome (HR 2.36, 95% CI 1.28–4.35, P¼0.006 and HR 2.21, 95%
CI 1.12–4.34, P¼0.02, respectively). Midgut location of tumours
was not confirmed to be an independent prognostic factor.
Survival analysis
At the end of follow-up, 72 patients had died, 47 were alive
(censored patients). Median OS (mOS) of the entire group was 3.2
years (95% CI 2.5–3.9) with a 2-year survival rate (2-y-OS) of
64.3% (95% CI 73–52%). Median follow-up was 2.3 years (95% CI
0.4–13.4). Overall survival was significantly shorter for PDNECs,
with a mOS of 1.3 years and a 2-y-OS of 41.7%, compared to 3.4
years and 66.2%, respectively, for WDNECs, P¼0.002 (Figure 1A).
Risk model for WDNCs
A subanalysis restricted to WDNEC was performed to identify
subgroups of these patients with different prognoses. The
Table 2 Univariate and multivariate analysis of factors prognostic for
survival of the entire cohort
Univariate analysis
Variable Group N HR 95% CI P-value
Sex Females 60 1
Males 59 0.73 0.45–1.17 0.190
Age (years) o60 63 1
460 56 1.04 0.65–1.66 0.862
Primary site Hindgut 4 1
Foregut 26 0.22 0.07–0.70 0.01
Midgut 53 0.16 0.05–0.48 0.001
Unknown GI 36 0.30 0.10–0.89 0.029
Primary site Midgut 53 1
Other sites 66 1.74 1.08–2.81 0.023
Metastases Liver 44 1
Liver+other 42 1.45 0.83–2.53 0.19
Other 33 0.98 0.54–1.80 0.96
Histology Well-differentiated 110 1
Poorly differentiated 9 3.37 1.50–7.55 0.003
Histology Non-carcinoid 41 1
Carcinoid 78 0.86 0.53–1.40 0.542
Functioning No 74 1
Yes 45 1.18 0.73–1.91 0.5
LFTs Non-signif. altered 84 1
Signif. altered 21 2.08 1.17–3.72 0.013
U5HIAA Non-signif. altered 48 1
Signif. altered 48 1.87 1.08–3.24 0.025
Multivariate analysis
Histology Well-differentiated 84 1
Poorly differentiated 6 4.02 1.26–12.82 0.02
U5HIAA Non-signif. altered 46 1
Signif. altered 44 2.36 1.28–4.35 0.006
LFTs Non-signif. altered 73 1
Signif. altered 17 2.21 1.12–4.34 0.02
Variables not significant in multivariate analysis
Primary site Midgut 47
Other sites 43 0.06
N¼absolute number of patients; CI¼confidence interval; HR¼hazard ratios;
LFTs¼Liver function tests; signif.¼significantly; u5HIAA¼urinary 5-hydroxyindole
acetic acid; Unknown GI¼unknown primary site with abdominal lesions as main site
of disease.
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Figure 1 (A) Overall survival according to histological differentiation.
WDNEC: well-differentiated neuroendocrine carcinoma; PDNEC: poorly
differentiated neuroendocrine carcinoma. (B) Overall survival according to
histological differentiation and the three risk groups for WDNEC; low-risk
WDNEC: patients with both LFTs and u5HIAA not significantly altered;
intermediate-risk WDNEC: patients with either LFTs or u5HIAA
significantly altered; high-risk WDNEC: patients with both LFTs and
u5HIAA significantly altered.
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statistically significant prognostic factors (HR¼2.65, 95% CI
1.33–5.30, P¼0.006 and HR¼2.51, 95% CI 1.35–4.63, P¼0.003,
respectively) (Table 3).
Liver function tests and u5HIAA were used to generate a
WDNEC-specific prognostic model. The model identified three
main classes of patients: (1) low-risk WDNECs¼patients with
both LFTs and 5HIAA not significantly altered; (2) intermediate-
risk WDNECs¼patients with one of the two variables significantly
altered; and (3) high-risk WDNECs¼patients with both LFTs and
5HIAA significantly altered.
A survival analysis was performed with both Kaplan–Meier and
Cox-regression methods comparing the three WDNEC risk classes
with PDNECs. Poorly differentiated neuroendocrine carcinomas
displayed the shortest OS (mOS¼1.3 years, 95% CI 0.1–2.8), but
this was close to the survival of high-risk WDNEC patients
(mOS¼1.4 years, 95% CI 0.7–2.0) (Figure 1B). There was no
significant difference between these two groups at Cox-regression
analysis (HR¼1.33, 95% CI 0.49–3.62, P¼0.572) (Table 4). Low-
risk WDNECs showed the most favourable prognosis (mOS 8.1
years, 95% CI 5.3–10.9), with a statistically significant difference
when compared to both intermediate risk (mOS 3.2 years, 95% CI
1.4–5.1) and high risk (see above) (Figure 1B). On Cox-regression
analysis, using low-risk WDNECs as the reference, HRs and
P-values were HR¼2.44, P¼0.01 and HR¼6.07, P¼0.0001 for
intermediate-risk WDNECs and high-risk WDNECs, respectively
(Table 4).
DISCUSSION
This study is the first reported single-centre data set selecting
patients with metastatic GEP NET at diagnosis. Our retrospective
analysis confirms the prognostic utility of histological differentia-
tion according to the WHO classification. In addition, significant
elevation of u5HIAA and/or LFTs predicts for decreased survival
for patients with WDNEC.
Five-year OS for patients with metastatic NETs has been
reported ranging from 26 to 73% in previous large series, showing
a rather variable survival that needs to be further stratified
(Eriksson et al, 1990; Madeira et al, 1998; Hochwald et al, 2002;
Modlin et al, 2003).
The impact of histological differentiation on prognosis has been
previously well documented. In a study by Madeira et al (1998)
including NETs from the duodenopancreatic area and excluding
carcinoids, PDNECs in patients presenting with liver metastases
were associated with an HR for death of 8.11 (multivariate
analysis). The rates of WDNECs and PDNECs were comparable to
those observed in our study (WDNECs 78%, PDNECs 11%, non-
evaluated 11%). In another study including only NETs of the
stomach, mOS for PDNECs was 8 months (Rindi et al, 1999). In
our analysis, histological differentiation was confirmed to be an
independent prognostic factor, with the highest impact on OS.
Poorly differentiated neuroendocrine carcinomas were associated
with an mOS almost 2.5 times shorter than that observed for
WDNECs (1.3 vs 3.4 years, P¼0.002). Multivariate analysis showed
a relative risk of death four times higher (P¼0.02).
Poorly differentiated neuroendocrine carcinomas, however,
were confirmed to represent only a small percentage of cases
(8%), and on the remaining group (92% of patients) other
discriminatory factors had to be applied. Univariate analysis
showed u5HIAA level, site of origin (based on the distinction
between midgut and non-midgut tumours) and LFT values to be
significantly associated with prognosis, but only u5HIAA and LFTs
were independent prognostic factors in the multivariate analysis
(HR 2.4, P¼0.006 and HR 2.2 P¼0.02, respectively).
Urinary 5-hydroxyindoleacetic acid level was observed to be
widely variable in WDNECs and, interestingly 10 patients not
diagnosed as carcinoid tumours presented with significantly raised
u5HIAA at diagnosis. Although it is well known that a given type of
NET may secrete several bioactive hormones, the urinary excretion
of 5HIAA in non-carcinoid tumours has rarely been documented.
In a study by Meijer et al (2000) including a mixed population of
healthy people, carcinoid NET patients, non-carcinoid NET
patients and non-neuroendocrine cancer patients (688 subjects
in total), 25 non-carcinoid NETs were associated with raised
u5HIAA level and for 7 of these ‘high-levels’ of u5HIAA (higher
than 2.4 times the ULN) were observed. Its prognostic influence,
however, has been previously reported (Janson et al, 1997; Onaitis
et al, 2000). An increasingly evaluated prognostic marker for NET,
the tumour marker CgA, was not included in our analysis as it was
not available for many patients (Baudin et al, 2001). Other studies
including CgA are warranted.
Radiological degree of liver involvement in NETs is a well-
documented prognostic factor (Janson et al, 1997; Madeira et al,
1998; Kouvaraki et al, 2004). Number of liver metastases (more
than four) and proportion of liver volume involved (more than
75%) have been shown to correlate with poorer OS (Janson et al,
1997; Kouvaraki et al, 2004). We postulated that serum
biochemical parameters such as gammaGT, ALT and bilirubin
might provide prognostic information via a functional assessment
of liver impairment. Our results showed that raised LFTs (Xgrade
2) are associated with a worse prognosis compared to patients with
a grade 0–1 biochemical liver function. Radiological evidence of
liver involvement alone was not significant for survival (P¼0.960).
Table 3 Multivariate analysis of factors prognostic for survival in selected
patients with WDNEC
Variable Group N HR 95% CI P-value
u5HIAA Non-signif. altered 40 1
Signif. altered 44 2.51 1.35–4.63 0.003
LFTs Non-signif. altered 69 1
Signif. altered 15 2.65 1.33–5.30 0.006
Primary site Midgut 46 1
Other sites 38 1.86 1.04–3.31 0.03
CI¼confidence interval; HR¼hazard ratio; LFTs¼liver function tests; N¼absolute
number of patients; signif.¼significantly; u5HIAA, urinary 5-hydroxyindole acetic acid;
WDNEC¼well-differentiated neuroendocrine carcinoma.
Table 4 HRs and mOS for the three different WDNEC risk groups and PDNEC
Group N mOS (years) HR 95% CI P-value HR 95% CI P-value
Low-risk WDNEC 35 8.1 1
Intermediate-risk WDNEC 39 3.2 2.44 1.24–4.80 0.01
High-risk WDNEC 10 1.4 6.07 2.51–14.65 0.0001 1
PDNEC 9 1.3 8.09 3.05–21.48 o0.0001 1.33 0.49–3.62 0.572
CI¼confidence interval; HR¼hazard ratio; LFTs¼liver function tests; mOS¼median overall survival; N¼absolute number of patients; PDNEC¼poorly differentiated
neuroendocrine carcinoma; WDNEC¼well-differentiated neuroendocrine carcinoma. Low-risk WDNEC, patients with both LFTs and u5HIAA not significantly altered;
intermediate-risk WDNEC, patients with either LFTs or u5HIAA significantly altered; high-risk WDNEC, patients with both LFTs and u5HIAA significantly altered.
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studies, we could not demonstrate an impact of age and sex on
prognosis (Janson et al, 1997; Hochwald et al, 2002).
From our analysis, it appears that functional liver impairment,
as defined by elevation of LFTs Xgrade 2, in combination
with u5HIAA, can provide a simple and objective method for
stratifying WDNEC patients in three prognostic classes. Patients
were reasonably well distributed among the three classes (42, 46
and 12%, for LR, IR and HR-WDNECs, respectively) and
survival differences were statistically significant. Looking at
the Kaplan–Meier curves, high-risk WDNECs tend to have similar
prognosis to PDNECs (mOS: 1.4 and 1.3 years, respectively),
whereas low-risk and intermediate-risk WDNECs showed two
distinct survival curves with an mOS of 8.1 and 3.2 years,
respectively.
This single-centre series supports the prognostic value of the
WHO classification for NETs. In addition, the analysis demon-
strates that additional prognostic information may be gained by
measuring u5HIAA and LFTs. Our proposed score may allow more
accurate prognostic assessment within this heterogeneous patient
population, although it needs to be confirmed in an independent
data set. More importantly, improved risk stratification is critical
for the development of future clinical trials. The identification of
poor risk subgroups with WDNEC will hopefully assist in
developing novel therapies for this relatively neglected group of
patients.
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